TITLE

Placebo controlled, randomised, double blind study of the effects of botulinumA toxin on detrusor sphincter dyssynergia in multiple sclerosis patients

AUTHOR(S)
Gallien, P.; Reymann, J.-M.; Amarenco, G.; Nicolas, B.; de Sèze, M.; Bellissant, E.
PUB. DATE
December 2005
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Dec2005, Vol. 76 Issue 12, p1670
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: The purpose of the study was to evaluate the efficacy and safety of botulinum A toxin in the treatment of detrusor sphincter dyssynergia in multiple sclerosis patients. Methods: This was a multicentre, placebo controlled, randomised, double blind study. Patients with chronic urinary retention were included if they had post-voiding residual urine volume between 100 and 500 ml. They received a single transperineal injection of either botulinum A toxin (100 U Allergan) or placebo in the sphincter and also 5 mg slow release alfuzosin bid over 4 months. Main endpoint was post- voiding residual urine volume assessed 1 month after injection. Follow up duration was 4 months. Statistical analysis was performed using a sequential method, the triangular test. Results: The study was stopped after the fourth analysis (86 patients had been included: placebo: 41, botulinum A toxin: 45). At inclusion, there was no significant difference between groups whichever variable was considered. Mean (standard deviation) post-voiding residual urine volume was 217(96) and 220 (99) ml in placebo and botulinum A toxin groups, respectively. One month later, post-voiding residual urine volume was 206 (145) and 186 (158) ml (p=0.45) in placebo and botulinum A toxin groups, respectively. However, compared to placebo, botulinum A toxin significantly increased voiding volume (+54%, p=0.02) and reduced pre-micturition (-29%, p=0.02) and maximal (-21%, p=0.02) detrusor pressures. Other secondary urodynamic endpoints and tolerance were similar in the two groups. Conclusions: In multiple sclerosis patients with detrusor sphincter dyssynergia, a single injection of botulinum A toxin (100 U Allergan) does not decrease post-voiding residual urine volume.
ACCESSION #
19236632

 

Related Articles

  • Efficacy and Safety of Botulinum Toxin A Injection Compared with Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure: A Prospective Randomized Study. Fruehauf, Heiko; Fried, Michael; Wegmueller, Barbara; Bauerfeind, Peter; Thumshirn, Miriam // American Journal of Gastroenterology;Sep2006, Vol. 101 Issue 9, p2107 

    OBJECTIVES: To evaluate the efficacy and safety of botulinum toxin A injection compared with topical nitroglycerin ointment for the treatment of chronic anal fissure (CAF). METHODS: Fifty outpatients with CAF were randomized to receive either a single botulinum toxin injection (30 IU Botox®)...

  • Neurology: Study: Botulinum toxin a shot in the arm for preventing MS tremor.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article discusses the use of Botulinum toxin that may help in preventing tremor in the arms and hands of people with multiple sclerosis (MS).

  • The Myriad Uses of Botulinum Toxin. Pullman, Seth L. // Annals of Internal Medicine;12/6/2005, Vol. 143 Issue 11, p838 

    The article presents information about the uses of Botulinum Toxin (BTx). BTx is an important therapeutic agent with widespread applications in neurologic and non-neurologic disease. Double-blind, placebo-controlled clinical trials have shown that BTx safely and effectively resolves excessive...

  • Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Giovannelli, M.; Borriello, G.; Castri, P.; Prosperini, L.; Pozzilli, C. // Clinical Rehabilitation;Apr2007, Vol. 21 Issue 4, p331 

    Objective: To determine whether additional physiotherapy increases botulinum toxin type A effects in reducing spasticity in patients with multiple sclerosis. Design: A single-blind, randomized, controlled pilot trial with a 12-week study period. Subjects: Thirty-eight patients with progressive...

  • A literature review on the role of chemical sphincterotomy after Milligan-Morgan hemorrhoidectomy. Siddiqui, Muhammad Rafay Sameem; Abraham-Igwe, Chuk; Shangumanandan, Arun; Grassi, Veronica; Swift, Ian; Abulafi, Al Mutaz // International Journal of Colorectal Disease;Jun2011, Vol. 26 Issue 6, p685 

    Objective: A literature review of agents used to induce chemical sphincterotomy after hemorrhoidectomy. Methods: Electronic databases were searched from January 1935 to August 2010. Results: Two randomized controlled trials compared calcium channel blockers (Ca2) with placebo. Pain appeared to...

  • Botulinum toxin and anal fissure: Efficacy and safety systematic review. Yiannakopoulou, Eugenia // International Journal of Colorectal Disease;Jan2012, Vol. 27 Issue 1, p1 

    Purpose: The main purpose of this study was to investigate the efficacy and safety of botulinum toxin in the treatment of anal fissure. An answer was attempted to the following research questions: (i) what is the efficacy of botulinum toxin in healing of anal fissure compared to placebo, (ii)...

  • Botulinum toxin.  // Mayo Clinic Health Letter;Dec2006, Vol. 24 Issue 12, p4 

    The article talks about botulinum toxin known as miracle poison which can help people better manage conditions that range from swallowing difficulties to painful, involuntary muscle spasms, spasms related to Parkinson's disease and multiple sclerosis or stroke. Botulinum toxin is a product of...

  • FDA approves Botox for spasticity.  // Momentum (19403410);Summer2010, Vol. 3 Issue 3, p13 

    The article provides information about the approval of the U.S. Food and Drug Administration of the use of the drug Botox or onabotulinumtoxin A on people who have experienced stroke, traumatic brain injury, or multiple sclerosis (MS).

  • First placebo-controlled trial of Botox for incontinence.  // Inside MS;Dec2005/Jan2006, Vol. 23 Issue 6, p34 

    The article reports on a clinical trial of botulinum toxin type A. A study was conducted to determine the effect of botulinum toxin on neurogenic overactive bladder, which is a kind of urinary incontinence associated with multiple sclerosis. Results showed that those who were injected with the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics